PubMed Health⌕ Search

Biomedical subjects

L Restrepo

Publications and source records attributed to L Restrepo.

10 recordsLinked to original sources

Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis.

BACKGROUND: Prestroke statin use may improve ischemic stroke outcomes, yet there is also evidence that statins and extremely low cholesterol levels may increase the risk of intracranial hemorrhage. We evaluated the independent effect of statin use and admission cholesterol level on risk of symptomatic hemorrhagic transformation (sHT) after recanalization therapy for acute ischemic stroke. METHODS: We analyzed ischemic stroke patients recorded in a prospectively maintained registry that received recanalization therapies (IV or intra-arterial fibrinolysis or endovascular embolectomy) at a university medical center from September 2002 to May 2006. The independent effect of premorbid statin use on sHT post intervention was evaluated by logistic regression, adjusting for prognostic and treatment variables known to predict increased HT risk after ischemic stroke. RESULTS: Among 104 patients, mean age was 70 years, and 49% were men. Male sex, hypertension, statin use, low total cholesterol and low-density lipoprotein (LDL) cholesterol, current smoking, elevated glucose levels, and higher admission NIH Stroke Scale (NIHSS) score were all associated with a greater risk of sHT in univariate analysis. After adjusting for covariates, low LDL cholesterol (odds ratio [OR], 0.968 per 1-mg/dL increase; 95% CI, 0.941 to 0.995), current smoking (OR, 14.568; 95% CI, 1.590 to 133.493), and higher NIHSS score (OR, 1.265 per 1-point increase; 95% CI, 1.047 to 1.529) were independently associated with sHT risk. CONCLUSIONS: Lower admission low-density lipoprotein cholesterol level with or without statin use, current smoking, and greater stroke severity are associated with greater risk for symptomatic hemorrhagic transformation after recanalization therapy for ischemic stroke.

Aged↗

Aggregation of sphalerite: role of zinc ions.

Sphalerite from six sources is shown to aggregate at ca. pH 7-9, confirmed by different techniques (settling velocity, suspension analysis, and optical microscopy). This does not correlate with the isoelectric point, which is consistently < pH 6. A similar observation was made by Healy and Jellet [J. Colloid Interface Sci. 24 (1967) 41-46] for ZnO (and reconfirmed here), who suggested Zn hydrolysis products were responsible. The hypothesis is tested using chalcopyrite and silica suspensions in the presence of Zn ions. It is found that aggregation occurs over the same pH range, 7-9. Solution and surface analysis (extraction by EDTA) shows sphalerite released sufficient Zn ions to promote aggregation. The pH range 7-9 corresponds to hydroxide formation, suggesting this is the species responsible. Aggregation of sphalerite due to the polymerization/flocculation action of zinc hydroxide is proposed.

Journal Article↗

Reversible tacrolimus-induced neurotoxicity isolated to the brain stem.

Diplopia, nystagmus, visual hallucinations, and internuclear ophthalmoplegia developed in a 30-year-old woman 84 days after she received a matched, unrelated bone marrow transplant for chronic myeloid leukemia. A regimen of tacrolimus had been administered since the transplantation was performed. MR imaging revealed bilaterally symmetric regions of signal abnormality with abnormal contrast enhancement in the brain stem. No supratentorial abnormality was present. Tacrolimus therapy was discontinued, and the symptoms resolved. MR imaging that was performed 10 days after tacrolimus was discontinued showed resolution of the abnormalities.

Adult↗

[Communication].

Explore the source record for details and available documents.

Communication↗

[Group processes].

Explore the source record for details and available documents.

Group Processes↗